Long-term quality of life improvements seen in children treated with ixekizumab
Click Here to Manage Email Alerts
MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
“About 1% of children and adolescents worldwide are affected by plaque psoriasis (PsO),” Andreas Pinter, MD, medical director of clinical research and senior physician in the department of dermatology at University Hospital Frankfurt, and colleagues wrote. “Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A.”
This data, from a 108-week extension period of the IXORA-PEDS trial, included 77 patients who received ixekizumab every 4 weeks at doses determined by weight.
An improvement in Itch Numeric Rating Scale (NRS) score of at least 4 points was reported in 75% of patients at week 12 and 84.9% at week 108, while Itch NRS 0 response was reported by 54.5% of patients at week 12 and 62.5% at week 108.
DLQI improvement to 0 or 1 was reported by 67% of patients at week 12 and 76% of patients at week 108.
The mean change in NRS score was maintained through week 108 at –4.3.
“Pediatric patients treated with ixekizumab experienced meaningful improvements in PsO outcomes and health-related [quality of life] through 108 weeks after treatment initiation,” the authors wrote.
Collapse
Pinter A, et al. Poster. Patient reported outcomes following long-term ixekizumab treatment up to 108 weeks in pediatric patients with plaque psoriasis. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 7-10, 2022; Milan.
Read more about
Click Here to Manage Email Alerts